Establishment Labs Holdings (ESTA) Liabilities and Shareholders Equity (2017 - 2026)
Establishment Labs Holdings (ESTA) recorded quarterly Liabilities and Shareholders Equity of $351.0 million in Q1 2026, down 1.72% quarter-over-quarter from $357.2 million in Q4 2025, and up 5.3% on a YoY basis from $333.4 million in Q1 2025.
Establishment Labs Holdings (ESTA) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Establishment Labs Holdings' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $351.0 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 5.3% year-over-year to $351.0 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 10.32% YoY), while the FY2025 annual figure was $357.2 million, up 2.98% from the prior year.
- Liabilities and Shareholders Equity was $351.0 million for Q1 2026 at Establishment Labs Holdings, down from $357.2 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $357.2 million in Q4 2025 to a low of $141.6 million in Q1 2022.
- Historically, Liabilities and Shareholders Equity has averaged $276.5 million across 5 years, with a median of $285.1 million in 2024.
- Biggest YoY gain for Liabilities and Shareholders Equity was 51.27% in 2022; the steepest drop was 7.08% in 2022.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $211.1 million in 2022, then rose by 27.28% to $268.6 million in 2023, then increased by 29.11% to $346.8 million in 2024, then gained by 2.98% to $357.2 million in 2025, then retreated by 1.72% to $351.0 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $351.0 million (Q1 2026), $357.2 million (Q4 2025), and $338.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 91.49 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 31.92 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 6.63 Bn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 37.13 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 10.74 Bn |
| 10 | Establishment Labs Holdings | 2.54 Bn | 2.47 Bn | 42.34 Mn | 351.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 351.04 Mn |
| Dec 31, 2025 | 357.17 Mn |
| Sep 30, 2025 | 338.90 Mn |
| Jun 30, 2025 | 329.67 Mn |
| Mar 31, 2025 | 333.36 Mn |
| Dec 31, 2024 | 346.83 Mn |
| Sep 30, 2024 | 282.69 Mn |
| Jun 30, 2024 | 285.09 Mn |
| Mar 31, 2024 | 301.84 Mn |
| Dec 31, 2023 | 268.64 Mn |
| Sep 30, 2023 | 270.53 Mn |
| Jun 30, 2023 | 285.30 Mn |
| Mar 31, 2023 | 209.36 Mn |
| Dec 31, 2022 | 211.06 Mn |
| Sep 30, 2022 | 187.65 Mn |
| Jun 30, 2022 | 199.88 Mn |
| Mar 31, 2022 | 141.56 Mn |
| Dec 31, 2021 | 139.53 Mn |
| Sep 30, 2021 | 148.36 Mn |
| Jun 30, 2021 | 152.12 Mn |